This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact The Epoch Times Reprints.
U.S. regulators on April 1 approved an obesity pill called Foundayo from Eli Lilly, adding a second option for consumers who want to take weight loss drugs but desire to avoid injections.
Foundayo is a glucagon-like peptide-1 (GLP-1) medication meant to be taken once a day.